WILLIAM TALLMADGE: Open Payments
NPI 1912080813 · TYLER, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,089 in 109 payments from 26 companies in 2025. Trend: 2023 $1,292 · 2024 $1,442 · 2025 $2,089
Food & beverage: $2,010Education: $79
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 39 | $567 |
| GENZYME CORPORATION | 9 | $249 |
| AstraZeneca Pharmaceuticals LP | 8 | $174 |
| Insmed, Inc. | 8 | $174 |
| Actelion Pharmaceuticals US, Inc. | 3 | $129 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $83 |
| Electromed, Inc. | 5 | $68 |
| ABBVIE INC. | 3 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $62 |
| VERTEX PHARMACEUTICALS INCORPORATED | 3 | $62 |
Products named: DUPIXENT, TRELEGY ELLIPTA, NUCALA, Arikayce, OPSUMIT, AIRSUPRA, SMARTVEST, GLASSIA.
Industry payments across TX — which companies pay providers there.
